Tideway raises $27M round for IT automation software
A large round of $27 million has gone to IT automation software maker Tideway, which helps automate and streamline some of the processes that information technology departments generally do manually.
The company, which is based in New York and London, has software that can examine a company’s IT infrastructure and use the resulting data to create a continuously updated map of the structure and interdependencies of its physical and virtual networks.
Having such maps helps the company’s… Continue Reading
Life-science briefing: Wednesday, March 19, 2008
TODAY’S HEADLINES:
Paris-based Stentys takes $18M for “bifurcated” stents (release)
Blood analyzer IntelliDx raises $22M (PDF release)
Cancer-test biotech Calderome changes name to VeraCyte (VentureWire)
Predictive Biosciences names Peter Klemm as CEO (release)
Paris-based Stentys takes $18M for “bifurcated” stents – Stentys, a Paris-based medical device maker, raised $18 million in a second funding round. The company is developing “bifurcated” stents intended to prop open clogged arteries at blood-vessel junctions.
The startup said the funding will allow it to complete clinical trials… Continue Reading
BioVex raises $22M for cancer-killing viruses
Woburn, Mass.-based BioVex, a biotech working on new ways to attack cancer and infections, raised $22 million in a fifth funding round. Triathlon Medical Ventures led the round, joined by New Science Ventures, Forbion Capital Ventures, Avalon Ventures, Credit Agricole Private Equity, GeneChem Management, Innoven Partners and Scottish Equity Partners.
BioVex is developing so-called oncolytic viruses, which are designed to infect and destroy tumor cells — long a promising but never-proven anti-cancer technique. The company put… Continue Reading